Today: 11 July 2026
Browse Category

Stock Market 5 May 2026 - 6 May 2026

Cellectar Biosciences Stock: $140 Million Deal Puts Iopofosine FDA Filing in Focus

Cellectar Biosciences Stock: $140 Million Deal Puts Iopofosine FDA Filing in Focus

Cellectar Biosciences on Tuesday secured up to $140 million in new funding and rolled out fresh 12-month results for its iopofosine I 131 program, giving the cancer drug maker a shot of cash for a planned confirmatory trial and a potential U.S. submission in Waldenström macroglobulinemia. The company pegged the overall response rate at 83.6% from its Phase 2b CLOVER WaM trial, targeting this rare blood cancer.
Fiserv Stock Slides After Revenue Miss: Why Its 2026 Turnaround Just Got Harder

Fiserv Stock Slides After Revenue Miss: Why Its 2026 Turnaround Just Got Harder

Fiserv Inc. shares dropped 9.9% to $56.59 on Tuesday after the payments and financial tech firm missed Wall Street’s first-quarter revenue target. Disappointing results in both its Merchant Solutions and Financial Solutions segments fueled uncertainty about how quickly the company can deliver a turnaround. Shares of Fidelity National Information Services and Global Payments were also in the red.
Go toTop